Skip to main content

Advertisement

SpringerLink
Log in

Optimising the Economic Efficiency of Drug Studies

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

The cost of the development of a new drug product. from concept and synthesis of a new chemical entity to safety and efficacy testing. to the approval process and postmarketing surveillance, has more than quadrupled in the last 20 years. To amortise these costs. the pharmaceutical industry has taken on international dimensions. These efforts will not be enough. This review outlines many cost-saving and cost-containment suggestions that have been instituted or that need to be instituted in order to bring cost-effective drug therapy to individual patients. As the cost of illness continues to increase worldwide, it is imperative that new and cost-effective medications be developed and brought to worldwide markets.

This article considers components of the drug discovery and development processes which are likely to be inefficient and correctable. It further reviews current knowledge about the conduct of different parts of the processes, including different types of clinical trials and proposals that have been made to address these in an efficient manner. Documented and proposed cost-containment measures are presented, using several large scale trials as examples. Particular emphasis is placed on statistical methods and their contribution to either efficiencies or inefficiencies. No facet of the drug/product development should be overlooked in the attempt to reduce costs, from reducing the time it takes to bring a product to market to simple but too-frequently occurring errors, such as failing to have trial material at hand at the optimum time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anon. Calcitonin labelling change recommended. Drug Therapy 20: 14, 29, 1991

  • Anon. Pharma success 2 in 100 000. Scrip 3: 26, 1992

  • Antman K, Schnipper LE, Frei E. The crisis in clinical cancer research. Third-party insurance and investigational therapy. New England Journal of Medicine 319: 46–48, 1988

    Article  PubMed  CAS  Google Scholar 

  • Baker SG, Heidenberger K. Choosing sample sizes to maximize expected health benefit subject to a constraint on total trial costs. Medical Decision Making 9: 14–25, 1989

    Article  PubMed  CAS  Google Scholar 

  • Bassi RT. Personal communication, 1992

  • Bassler TJ, Bassler n. Long-term mortality after primary prevention for cardiovascular disease. Correspondence. Journal of the American Medical Association 267: 2183, 1992

    Article  PubMed  CAS  Google Scholar 

  • Berger R, Thiess M. European Mergers and acquisitions In the pharmaceutical industry. Drugs Made in Germany 35: 3–9, 1992

    Google Scholar 

  • Bigorra J, Banos JE. Weight of financial reward in the decision by medical students and experienced healthy volunteers to participate in clinical trials. European Journal of Clinical Pharmacology 38: 443–446, 1990

    Article  PubMed  CAS  Google Scholar 

  • Bulpitt CJ, Fletcher AE. Measuring costs and financial benefits in randomized controlled trials. American Heart Journal 119: 766–771, 1990

    Article  PubMed  CAS  Google Scholar 

  • Buring JE, Hennekens CH. Cost and efficiency in clinical trials: The U.S. Physicians’ Health study. Statistics in Medicine 9: 29–33, 1990

    Article  PubMed  CAS  Google Scholar 

  • Colburn WA, Blue JW. Using pharmacokinetics and pharmacodynamics to direct pharmaceutical R & D. Applied Clinical Trials 1: 42–46, 1992

    Google Scholar 

  • Csernansky JG, Newcomber JW, Miller S, Faustman WO. Clinical factors that may confound the assessment of drug efficacy. Psychopharmacology Bulletin 27: 231–235, 1991

    PubMed  CAS  Google Scholar 

  • Csernansky JG, Overall JE. Clinical trials in the’ 90s: new problems and new methodologies. Psychopharmacology Bulletin 27: 209–210, 1991

    Google Scholar 

  • Davies J, Glutz von Blotzheim ABG. The role of the computer in clinical research: a review of the current position. Clinical Trials Journal 22: 1–7, 1985

    Google Scholar 

  • Dawkins K, Potter WZ. Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: focus on women. Psychopharmacology Bulletin 27: 417–440, 1991

    PubMed  CAS  Google Scholar 

  • Defesche CL, Personal communication. 1992

  • DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10: 107–142, 1991

    Article  PubMed  CAS  Google Scholar 

  • DiMasi JA. Rising research and development costs for new drugs in a cost containment environment. PharmacoEconomics 1(Suppl. 1): 13–20, 1992

    Article  PubMed  CAS  Google Scholar 

  • Dobbs J, Hardy M. Taking the first steps with CANDAs. Applied Clinical Trials 1: 36–37, 1992

    Google Scholar 

  • Dupont WD. Randomized vs. historical clinical trials: are the benefits worth the cost? American Journal of Epidemiology 122: 940–946, 1985

    PubMed  CAS  Google Scholar 

  • Echt DS, Liebson PR, Mitchell B, Peters RW, Obias-Manno D, et al. Mortality and morbidity in patients receiving encainide, flecainide. placebo: the Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine 324: 781–788, 1991

    Article  PubMed  CAS  Google Scholar 

  • Elia J. Stimulant and antidepressant pharmacokinetics in hyperactive children. Psychopharmacology Bulletin 27: 411–416, 1991

    PubMed  CAS  Google Scholar 

  • Eliasziw M, Donner A. A cost-function approach to the design of reliability studies. Statistics in Medicine 6: 647–655, 1987

    Article  PubMed  CAS  Google Scholar 

  • Ellenberg SS. Do large, simple trials have a place in the evaluation of AIDS therapies? Oncology 6: 55–63, 1992

    PubMed  CAS  Google Scholar 

  • Executive Office of the President. Budget of the United States Government. Fiscal Year 1992. Table 11.3. U.S. Government Printing Office, Washington. DC, 1991

    Google Scholar 

  • Farrar WB. Clinical trials access and reimbursement. Cancer 7: 1779–1783, 1991

    Google Scholar 

  • Ferber H. Personal communication. June 1992

  • Fletcher AE, Hunt RM, Bulpitt CJ. Evaluation of quality of life in clinical trials of cardiovascular disease. Medical Care 40: 557–566, 1987

    CAS  Google Scholar 

  • Food and Drug Administration. HHS News, April 9, 1992

  • Franco S. Personal Communication, 1992

  • Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1: 20–29, 1992

    Article  PubMed  CAS  Google Scholar 

  • Gafni A. Measuring the adverse effects of unnecessary hypertension drug therapy: QALYs vs HYE. Clinics of Investigative Medicine 14: 266, 270, 1991

    CAS  Google Scholar 

  • Geller B. Psychopharmacology of children and adolescents: pharmacokinetics and relationships of plasma/serum levels of response. Psychopharmacology Bulletin 27: 401–410, 1991

    PubMed  CAS  Google Scholar 

  • George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some critical event. Journal of Chronic Diseases 27: 15–24, 1974

    Article  PubMed  CAS  Google Scholar 

  • Glutz von Blotzheim ABG. Personal communication. June 1992

  • Glutz von Blotzheim ABG, McDonell J. Research planning and development: a review of planning control requirements in clinical research. Clinical Trials Journal 22: 119–128, 1985

    Google Scholar 

  • Grabowski H. Pharmaceutical research and development: returns and risk. CMR Annual Lecture. Centre for Medicine Research, Carshalton, Surrey, 1991

    Google Scholar 

  • Grabowski H, Vernon J. A new look at the returns and risks to pharmaceutical R & D. Management Science 36: 804–821, 1990

    Article  Google Scholar 

  • Greenhouse JU, Meyer MM. A note on randomization and selection bias in maintenance therapy clinical trials. Psychopharmacology Bulletin 27: 225–229, 1991

    PubMed  CAS  Google Scholar 

  • Greenhouse JB, Stangl D, Kupfer DJ, Prien RF. Methodologic issues in maintenance therapy clinical trials. Archives of General Psychiatry 48: 313–318, 1991

    Article  PubMed  CAS  Google Scholar 

  • Guess HA, Rudnick SA. Use of cost-effectiveness analysis in planning cancer chemoprophylaxis trials. Controlled Clinical Trials 4: 89–100, 1983

    Article  PubMed  CAS  Google Scholar 

  • Hansen RW. The pharmaceutical development process. Estimates of current development costs and times and the effects of regulatory changes. In Chien RI (Ed.) Issues in pharmaceutical economics. pp. 151–187. Lexington Books, Lexington, MA, 1979

    Google Scholar 

  • Heal DJ, Buckett WR. Development of antidepressant drugs for the 1990s: progress or procrastination? International Journal of Geriatric Psychiatry 6: 431–443, 1991

    Article  Google Scholar 

  • Henney JE, Greene T, Aronson N, Johnson JE, McCabe M, et al. Reimbursement concerns. Cancer 65: 2409–2410, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991

    Article  PubMed  CAS  Google Scholar 

  • Jaeschke R, Guyatt GH, Cook D. Quality of life instruments in the evaluation of new drugs. PharmacoEconomics 1: 84–93, 1992

    Article  PubMed  CAS  Google Scholar 

  • Johannesson M, Jonsson B. Cost-effectiveness analysis of hypertension treatment — a review of methodological issues. Health Policy 19: 55–78, 1991

    Article  PubMed  CAS  Google Scholar 

  • Kawachi I. Economic factors in the initiation of antihypertensive therapy. PharmacoEconomics 2: 324–334, 1992

    Article  PubMed  CAS  Google Scholar 

  • Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. Journal of Hypertension 9: 1991–208, 1991

    Article  Google Scholar 

  • Killer ME. The changing face of clinical trials: hypertension. Journal of Hypertension 6: S73–S80, 1988a

    Article  Google Scholar 

  • Killer ME. The elderly in clinical trials: hypertension. Journal of Hypertension 6(Suppl. 1): S73–S80, 1988b

    Google Scholar 

  • Killer ME. Clinical trials in the elderly: pivotal points. Clinics in Geriatric Medicine 6: 235–255, 1990

    Google Scholar 

  • Kitler ME. Clinical trials and clinical practice in the elderly: a focus on hypertension. Drugs and Aging 2: 86–94, 1992a

    Article  PubMed  CAS  Google Scholar 

  • Kitler ME. Differences in men and women in coronary artery disease. systemic hypertension and their treatment. American Journal of Cardiology. in press, 1992b)

    Google Scholar 

  • Kraemer HC. To increase power in randomized clinical trials without increasing sample size. Psychopharmacology Bulletin 27: 217–224, 1991

    PubMed  CAS  Google Scholar 

  • Lamy PP. Comparative pharmacokinetic changes and drug therapy in an older population. Journal of the American Geriatrics Society 30: S11–S19, 1982

    PubMed  CAS  Google Scholar 

  • Lamy PP. Physiological changes due to age: pharmacodynamic changes of drug action and implications for therapy. Drugs and Aging 1: 385–304, 1991

    Article  PubMed  CAS  Google Scholar 

  • Langland-Orban B, Cuddeback JK, Ives JE, Barton MJ. The impact of DRGs on clinical research centers. Medical Care 26: 510–514, 1988

    Article  PubMed  CAS  Google Scholar 

  • Lin K-M, Poland RE, Smith MW, Strickland TL, Mendoza R. Pharmacokinetics and other related factors affecting psychotropic responses in Asians. Psychopharmacology Bulletin 27: 427–440, 1991

    PubMed  CAS  Google Scholar 

  • Maling TJ. Compensation for medicine-induced injury in clinical trials. New Zealand Medical Journal 100: 223, 1987

    PubMed  CAS  Google Scholar 

  • McKenna RJ. Reimbursement issues in cancer clinical trials. Cancer 65(Suppl. 10): 2405–2406, 1990

    Article  PubMed  CAS  Google Scholar 

  • Mehrez A, Gafni A. Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs). PharrnacoEconomics 1: 338–345, 1992

    Article  CAS  Google Scholar 

  • Mendoza R, Smith MW, Poland RE, Lin K-M, Strickland TL. Ethnic psychopharmacology: the hispanic and native American perspective. Psychopharmacology Bulletin 27: 449–462, 1991

    PubMed  CAS  Google Scholar 

  • Mickey RM, Goodwin GD, Costanza MC. Estimation of design effect In community intervention studies. Statistics in Medicine 10: 53–64, 1991

    Article  PubMed  CAS  Google Scholar 

  • Moeller H, Oeser W. Drug master file/ global harmonization of quality standards. Drugs Made in Germany 35: 24–26, 1992

    Google Scholar 

  • Moussa MAA. Planning a clinical trial with allowance for cost and patient recruitment rate. Computer Programming in Bio-medicine 18: 173–180, 1984

    CAS  Google Scholar 

  • Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. British Medical Journal 301: 309–314, 1990

    Article  PubMed  CAS  Google Scholar 

  • Neu HC (Ed.). Lomefloxacin: development of a once-a-day quinoline. American Journal of Medicine 92: 1S–137S, 1992

  • Oldham RK. Who’s paying for new drugs? Nature 332: 795–798, 1988

    Article  PubMed  CAS  Google Scholar 

  • Olmstead FL. Improved organization and management of clinical trials. Applied Clinical Trials 1: 38–41, 1992

    Google Scholar 

  • Overall JE. Statistical efficiencies that the FDA should encourage. Psychopharmacology Bulletin 27: 211–216, 1991

    PubMed  CAS  Google Scholar 

  • Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, et al. Effect of milrinone on mortality in severe chronic heart failure. New England Journal of Medicine 325: 1468–1475, 1991

    Article  PubMed  CAS  Google Scholar 

  • Paul O, Hennekens CH. The latest report from Finland: a lesson in expectations. Journal of the American Medical Association 266: 1267–1268, 1991

    Article  PubMed  CAS  Google Scholar 

  • Peace KE. TMO: the trial management organization — a new system for reducing the time for clinical trials. Drug Information Journal 24: 257–264, 1990

    Article  Google Scholar 

  • Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, et al. Opportunities for integration of pharmacokinetics. pharmacodynamics. and toxicokinetics in rational drug development. Clinical Pharmacology and Therapeutics 51: 465–473, 1992

    Article  PubMed  CAS  Google Scholar 

  • Perry MC. Patients. profits. and progress. Missouri Medicine 86: 375–376, 1989

    PubMed  CAS  Google Scholar 

  • Piantadosi S, Patterson B. A method for predicting accrual, cost. and paper now in clinical trials. Controlled Clinical Trials 8: 202–215, 1987

    Article  PubMed  CAS  Google Scholar 

  • Poole-Wilson PA, Lindsay D. Advances in the treatment of chronic heart failure. British Medical Journal 304: 1069–1070, 1992

    Article  PubMed  CAS  Google Scholar 

  • Porta MS, Hartzema AG. The contribution of epidemiology to the study of drugs. In Hartzema et al. (Eds) Pharmacoepidemiology. An introduction, pp. 2–17, Harvey Whitney Books, Cincinnati, Ohio, 1991

    Google Scholar 

  • Prentice RL. Opportunities for enhancing efficiency and reducing cost in large scale disease prevention trials: a statistical perspective. Statistics in Medicine 9: 161–172, 1990

    Article  PubMed  CAS  Google Scholar 

  • Quitkin FM. Methodology of measuring the efficacy of antidepressants. Psychopharmacology 106 (Suppl.): S87–S89, 1992

    Article  PubMed  Google Scholar 

  • Reinhardt J, Hugener M. Personal communication, June 1992

  • Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Health Care Financing Review 7: 61–80, 1985

    PubMed  CAS  Google Scholar 

  • Rogers AS, Tilson HH. Postmarketing surveillance: the sponsor’s viewpoint. Proceedings of the Drug Information Association 20th Annual Meeting, San Diego, CA, 1984

  • Rubenstein LV, Gail MH, Santner TJ. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. Journal of Chronic Diseases 34: 469–479, 1981

    Article  Google Scholar 

  • Shoaf SE, Linnoila M. Interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications. Psychopharmacology Bulletin 27: 577–594, 1991

    PubMed  CAS  Google Scholar 

  • Sommer A, Zeger SL. On estimating efficacy from clinical trials. Statistics in Medicine 10: 45–52, 1991

    Article  PubMed  CAS  Google Scholar 

  • Sondik EJ, Brown BW, Silvers A. High risk subjects and the cost of large field trials. Journal of Chronic Diseases 27: 177–187, 1974

    Article  PubMed  CAS  Google Scholar 

  • Sonnefeld ST, Waldo DR, Lemieux JA, McKusick DR. Projections of national health expenditures through the year 2000. Health Care Financing Review 13: 1–5, 1991

    PubMed  CAS  Google Scholar 

  • Spilker B. Extrapolation of preclinical safety data to humans. Drug News and Perspectives 4: 211–216, 1991

    Google Scholar 

  • Steering Committee. Registration of pharmaceuticals for human use. A report on the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals. Drugs Made in Germany 35: 12–16, 1992

    Google Scholar 

  • Strandberg TE, Salomaa W, Naukkarinen VA, Vanhanen HT, Sarna SJ, et al. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. Journal of the American Medical Association 266: 1225–1229, 1991

    Article  PubMed  CAS  Google Scholar 

  • Strickland TL, Ranganath V, Lin K-M, Poland RE, Mendoza R, et al. Psychopharmacologic considerations in the treatment of black American populations. Psychopharmacology Bulletin 27: 441–448, 1991

    PubMed  CAS  Google Scholar 

  • Tarlov AR, Ware JE, Greenfield S, Nelson EC, Perrin E, et al. The medical outcomes study: an application of methods for monitoring the results of medical care. Journal of the American Medical Association 262: 925–930, 1989

    Article  PubMed  CAS  Google Scholar 

  • Testa MA, Lenderking WR. Interpreting pharmacoeconomic and Quality-of-life clinical trial data for use in therapeutics. PharmacoEconomics 2: 107–117, 1992

    Article  PubMed  CAS  Google Scholar 

  • Thornton JG, Lilford RJ, Johnson E. Decision analysis in medicine. British Medical Journal 304: 1099–1103, 1992

    Article  PubMed  CAS  Google Scholar 

  • Tielsch JM, West Jr KP. Cost and efficiency considerations in community-based trials of vitamin A in developing countries. Statistics in Medicine 9: 35–43, 1990

    Article  PubMed  CAS  Google Scholar 

  • Tifft CP, Chobanian AV. Are some antihypertensive therapies more efficacious than others in preventing complications and prolonging life? Hypertension 18(Suppl. 1): I–146–I–152, 1991

    Google Scholar 

  • Urban N, Baker M. The Women’s Health Trial as an investment. Medical Decision Making 9: 59–64, 1989

    Article  PubMed  CAS  Google Scholar 

  • Urban N, Self S, Kessler L, Prentice R, Henderson M, et al. Analysis of the costs of a large prevention trial. Controlled Clinical Trials 11: 129–146, 1990

    Article  PubMed  CAS  Google Scholar 

  • Vagelos PR. Are prescription drug prices high? Science 252: 1080–1084, 1991

    Article  Google Scholar 

  • Vere DW. Payments to healthy volunteers — ethical problems. British Journal of Clinical Pharmacology 32: 141–142, 1991

    Article  PubMed  CAS  Google Scholar 

  • Vogelzang NJ, Richards JM. Third-party reimbursement issues during a phase I trial of interleukin-2. Journal of the National Cancer Institute 81: 544–545, 1989

    Article  PubMed  CAS  Google Scholar 

  • Waller PC, Wood SM, Langman MJS, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. British Medical Journal 304: 1470–1472, 1992

    Article  PubMed  CAS  Google Scholar 

  • Weinstein WC. Cost-effective priorities for cancer prevention. Science 221: 17–73, 1983

    Article  PubMed  CAS  Google Scholar 

  • Weiss WB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. New England Journal of Medicine 26: 862–866, 1992

    Article  Google Scholar 

  • White JE. Who should pay? Journal of Clinical Oncology 9: 1320, 1991

    PubMed  CAS  Google Scholar 

  • Wiggins SN. The cost of developing a new drug. Pharmaceutical Manufacturers Association, Washington, DC, 1987

    Google Scholar 

  • Woggon B. Methodology of measuring the efficacy of antidepressants — European viewpoint. Psychopharmacology 106 (Suppl.): S90–S92, 1992

    Article  PubMed  Google Scholar 

  • Wood TA. The cost to patients of participating in clinical trials. Journal of the American Medical Association 261: 1105–1151, 1989

    Article  Google Scholar 

  • Yasko JM. A progress report on reimbursement of biotherapy: prospects for the 1990s. Oncology Nursing Forum 16(Suppl. 6): 42–47, 1989

    PubMed  CAS  Google Scholar 

  • Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal of the American Medical Association 266: 93–98, 1991

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Maison des Truites, CH-1182, Gilly, Switzerland

    Mary Ellen Kitler

Authors
  1. Mary Ellen Kitler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kitler, M.E. Optimising the Economic Efficiency of Drug Studies. PharmacoEconomics 2, 371–387 (1992). https://doi.org/10.2165/00019053-199202050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199202050-00005

Keywords

Search

Navigation